Pharmacogenomics – Implications in the Development of HIV-Associated Brain Disease

Author(s): Thorsten Nolting, Gabriele Arendt

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 8 , Issue 2 , 2009


Become EABM
Become Reviewer
Call for Editor

Abstract:

Pharmacogenomics is a relatively new field in HIV-research, especially when neurological issues are concerned. Influence of polymorphisms in CYP3A4, CYP2B6, CYP2D6, ABCB1, ABCG2, ABCC4, SLC22, SLC28, SLC29 and MMP9-genes on pharmacokinetic data is discussed in the article. Due to the lack of published studies, but promising results in the few existing publications, scientists should be encouraged to integrate neurological aspects in pharmacogenomics research.

Keywords: HIV, CNS, pharmacogenomics, pharmacogenetics, MMP9, SLC, ABC-transporter, cytochrome

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 2
Year: 2009
Page: [164 - 168]
Pages: 5
DOI: 10.2174/187152309789152101
Price: $65

Article Metrics

PDF: 4